recombinant MVA-based vaccine (Nouscom)

N/A

Report date: 2025/06/11 10:59:04

Base Information

Drug Namerecombinant MVA-based vaccine (Nouscom)
Drug Alias Namemodified vaccinia Ankara vector expressing IL-12 (Nouscom)MVA-SynE1-IL-12
ClassificationVaccines > Application > Therapeutic vaccineVaccines > Development/production technology > Recombinant vector vaccine
Mechanisms of ActionImmunomodulators
TargetsNot applicable
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryItaly
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesNouscom SRL
China Registration ClassN/A

Develop Information

Active CompaniesNouscom SRL
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A